WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

EMA

The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.

www.ema.europa.eu

EMA RSS Channel

Filters
List of articles in category EMA
Title Published Date
EMEA, EC and Health Canada agree implementation plan for confidentiality arrangement 14 April 2009
EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab) 20 February 2009
European Medicines Agency welcomes continuation of D:A:D study 04 February 2009
EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride) 21 November 2008
EMEA recommends suspension of the marketing authorisation of Acomplia 24 October 2008
European Medicines Agency recommends update of product information of Tysabri 26 September 2008
European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines 28 July 2008
EMEA recommendation on use of angiotensin II receptor antagonists during pregnancy 25 April 2008
Wyeth Europa Ltd withdraws its marketing authorisation application for Pristiqs (desvenlafaxine) 13 March 2008
Actelion withdraws its application for an extension of indication for Zavesca 27 February 2008
Risk of peripheral neuropathy with Sebivo (telbivudine) 15 February 2008
EMEA recommends new warnings and contraindications for rosiglitazone 25 January 2008
EMEA recommends withdrawal of marketing authorisations for cough medicines containing clobutinol 19 October 2007
  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End

Business & Industry

  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
  • GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
  • Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically

Research & Development

  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
  • A new technology offers treatment for HIV infection through a single injection

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. EMA
  4. EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.